January 04, 2024
HIROTSU Bio Science Inc.

Nematode cancer test “N-NOSE” exceeds 2,000 companies.
HIROTSU Bio Science Inc. (Head Office: Chiyoda-ku, Tokyo; Representative; Takaaki
Hirotsu (Hereinafter referred to as “HIROTSU”)), is proud to announce that the total
number of companies that have adopted N-NOSE has exceeded 2,000.
It is currently a challenge for individuals to take cancer control measures on their own, bothfinancially and mentally. However, companies can protect their valuable employees byrecommending it as a benefit program.
Our "N-NOSE" program began to be introduced in companies in April 2022, and about 70
companies have introduced it every month. In particular, many companies with irregular
working hours, such as those in the construction and transportation industries, have introduced
the system because "employees can decide where and when they want to submit their
documents on their own. We are honored to be able to help solve this problem, as "lack of time"is one of the major reasons why people do not take cancer screenings*1. We will continue ourefforts to solve various issues for the future of early cancer detection.
*1

Cabinet Office, 2023. ”がん対策に関する世論調査”■ Company Employee Testimonials
About 10 years ago, I had a biopsy for prostate cancer with high PSA, but there was noproblem and I was under observation. This year, my PSA level became high, and I was told tohave a detailed examination. About 2 years ago, N-NOSE was introduced as a company
benefit program, and I knew someone who was found to have early-stage colorectal cancer
through a precision examination because of the risk assessment. The result was a D grade.
After that, I requested a biopsy at a general hospital and found early-stage prostate cancer.

The surgery took about 4 hours, and I was hospitalized for 9 days. If treated early, there is noneed to stay in bed. It would be good if a simple examination is done first and leads to early
detection. It would be good if it spreads more and more to corporate health checkups.
(Male, suffering from prostate cancer)■ About HIROTSU Bio Science
We as HIROTSU aim to protect the health and future security of people through research,development, and practical application of unique technology that utilize the capabilities ofliving organisms. Established in 2016, N-NOSE was put into practical use thanks to ourresearchers` abundance of ideas and tireless efforts. Despite the importance of extending
healthy life expectancy being emphasized, it is said that one in every two people will bediagnosed with cancer in this age of 100-year life expectancy. We strive to contribute tosolving these social issues with our groundbreaking “bio-diagnoses” technology that utilizes
the power of nematodes.
Company Name: HIROTSU Bio Science Inc.

Headquarters: 22F New Otani Garden Court, 4-1 Kioi-cho, Chiyoda-ku, Tokyo

Representative: Takaaki Hirotsu, CEODate of Establishment : August 2016
Main Service: Research, development, and marketing of cancer screenings using
nematodes and nematode olfactory sensors

Official Website: https://hbio.jp/en/■ About “N-NOSE”
A primary screening test for cancer that utilizes the highly accurate detection of cancer-specificodors in human urine by the nematode C. elegans, which has a very good sense of smell. By
simply submitting urine, the test is simple, inexpensive, highly accurate, and provides a wholebody comprehensive examination of early-stage cancer risk.
Official Service Website: https://lp.n-nose.com/■ About “N-NOSE plus Pancreas”
N-NOSE's next-generation "Cancer Type Specific Test". This test uses a "special nematode"
genetically engineered from the nematode C. elegans that specifically reacts only to the smell

of pancreatic cancer. This "special nematode" has a high ability to distinguish between
pancreatic cancer and other cancers, enabling non-invasive detection of early-stage pancreaticcancer.
Official Service Website: https://lp.n-nose.com/suizou/■ About “N-NOSE Animals”“N-NOSE Dogs” and “N-NOSE Cats” developed based on the N-NOSE technology. Up until
now, there has not been an easily accessible cancer screening test for pets. Just like N-NOSE
for humans, starting in 2023, an easy cancer risk screening only requiring urine for both catsand dogs has been made available due to this product.
Official Service Website: https://lp.n-nose.com/animal/

Press Contact
HIROTSU Bio Science PRE-mail：press@hbio.jp